The biotechnology sector has long stood at the intersection of innovation and financial fragility. While biotech companies drive some of the most consequential advances in medicine, spanning oncology, gene therapies, immunology, and rare diseases, they also face structural challenges that consistently undermine their ability to scale. Long development timelines, binary clinical outcomes, regulatory uncertainty, and […]
The post Biotech at a Crossroads, How Utility-Driven Digital Asset Treasuries Could Redefine Capital Access and Growth first appeared on The UCW Newswire : Global Financial, Business and Tech News.
